Teva Pharmaceutical Industries Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Teva Pharmaceutical Industries de 32.1% y 2.2% por año respectivamente. Se prevé que el BPA crezca en un 37.1% al año. Se espera que la rentabilidad financiera sea de 25.3% en 3 años.
Información clave
32.1%
Tasa de crecimiento de los beneficios
37.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 23.0% |
| Tasa de crecimiento de los ingresos | 2.2% |
| Rentabilidad financiera futura | 25.3% |
| Cobertura de analistas | Good |
| Última actualización | 28 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 16,746 | 1,665 | 2,956 | 2,177 | 10 |
| 12/31/2025 | 16,346 | 1,442 | 2,862 | 2,230 | 11 |
| 12/31/2024 | 15,863 | 1,538 | 2,706 | 1,931 | 11 |
| 12/31/2023 | 15,846 | -559 | 842 | 1,368 | N/A |
| 9/30/2023 | 15,273 | -2,209 | 608 | 1,157 | N/A |
| 6/30/2023 | 15,017 | -2,234 | 1,173 | 1,695 | N/A |
| 3/31/2023 | 14,925 | -1,603 | 964 | 1,494 | N/A |
| 12/31/2022 | 14,925 | -2,446 | 1,042 | 1,590 | N/A |
| 9/30/2022 | 15,141 | -1,291 | 514 | 1,073 | N/A |
| 6/30/2022 | 15,433 | -1,054 | 476 | 1,059 | N/A |
| 3/31/2022 | 15,557 | -615 | 585 | 1,154 | N/A |
| 12/31/2021 | 15,878 | 417 | 236 | 798 | N/A |
| 9/30/2021 | 16,231 | 726 | 88 | 673 | N/A |
| 6/30/2021 | 16,324 | -3,915 | -131 | 451 | N/A |
| 3/31/2021 | 16,284 | -3,982 | -94 | 506 | N/A |
| 12/31/2020 | 16,659 | -3,990 | 638 | 1,216 | N/A |
| 9/30/2020 | 16,673 | -4,031 | 902 | 1,423 | N/A |
| 6/30/2020 | 16,788 | 4 | 894 | 1,441 | N/A |
| 3/31/2020 | 17,095 | -825 | 413 | 941 | N/A |
| 12/31/2019 | 16,887 | -999 | 223 | 748 | N/A |
| 9/30/2019 | 16,396 | -4,048 | -42 | 577 | N/A |
| 6/30/2019 | 16,831 | -4,007 | 84 | 673 | N/A |
| 3/31/2019 | 17,355 | -3,559 | 449 | 1,062 | N/A |
| 12/31/2018 | 18,271 | -2,399 | 1,795 | 2,446 | N/A |
| 9/30/2018 | 19,693 | -11,059 | 2,233 | 2,938 | N/A |
| 6/30/2018 | 20,781 | -10,256 | 2,534 | 3,312 | N/A |
| 3/31/2018 | 21,800 | -16,050 | 2,750 | 3,585 | N/A |
| 12/31/2017 | 21,853 | -16,525 | 1,351 | 2,225 | N/A |
| 9/30/2017 | 23,479 | -5,963 | N/A | 2,791 | N/A |
| 6/30/2017 | 23,425 | -6,145 | N/A | 3,457 | N/A |
| 3/31/2017 | 22,743 | 78 | N/A | 3,985 | N/A |
| 12/31/2016 | 21,903 | 68 | N/A | 3,890 | N/A |
| 9/30/2016 | 20,292 | 1,591 | N/A | 5,415 | N/A |
| 6/30/2016 | 19,552 | 1,346 | N/A | 5,047 | N/A |
| 3/31/2016 | 19,480 | 1,697 | N/A | 5,564 | N/A |
| 12/31/2015 | 19,652 | 1,573 | N/A | 5,542 | N/A |
| 9/30/2015 | 19,939 | 1,775 | N/A | 5,679 | N/A |
| 6/30/2015 | 20,174 | 2,548 | N/A | 6,010 | N/A |
| 3/31/2015 | 20,253 | 2,757 | N/A | 5,583 | N/A |
| 12/31/2014 | 20,272 | 3,055 | N/A | 5,127 | N/A |
| 9/30/2014 | 20,534 | 2,748 | N/A | 4,191 | N/A |
| 6/30/2014 | 20,535 | 2,583 | N/A | 3,211 | N/A |
| 3/31/2014 | 20,414 | 1,383 | N/A | 3,033 | N/A |
| 12/31/2013 | 20,314 | 1,269 | N/A | 3,237 | N/A |
| 9/30/2013 | 20,133 | 1,209 | N/A | 3,998 | N/A |
| 6/30/2013 | 20,046 | 419 | N/A | 4,602 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que TEVA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que TEVA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que TEVA sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (2.2% al año) de TEVA crezcan más despacio que el mercado de US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 2.2% al año) de TEVA crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de TEVA sea alta dentro de 3 años (25.3%)